Navigation Links
Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
Date:5/6/2009

PORTOLA VALLEY, Calif., May 6 /PRNewswire/ -- Spectros Corporation (Portola Valley, CA) filed in Federal District Court today against Thermo Fisher Scientific (NYSE: TMO), alleging infringement of Spectros' spectroscopy patent family by TMO's Nanodrop 3300 product. Spectros invented and commercialized solid-state, broadband, integrated spectroscopy light sources based on white LEDs, and incorporated these into its flagship T-Stat product, replacing hot light bulbs with cool illuminator sources. The Nanodrop 3300, introduced to market after T-Stat, also incorporates a white LED for spectroscopy. Thermo Fisher promotes this feature as "unconventional," yet TMO holds no published or issued patents covering this approach. Spectros previously approached TMO regarding specific infringed claims on US Patent no. 6,711,426, without success.

"We are surprised that Thermo Fisher Scientific has continued to market devices incorporating our novel and proprietary technology. We trust that, over time, TMO will appreciate the validity and value of the broad, early optical biotechnology intellectual property portfolio held by Spectros," notes David Benaron, CEO.

Spectros and its affiliates have over 80 issued and pending patents in the U.S., Europe, and Japan, forming one of the largest biophotonics intellectual property collections. Spectros' core patents cover optical spectroscopy, fluorimetry, and imaging for use in blood analysis, contrast-targeted cancer surgery, lab-on-chip systems, and benchtop life-sciences equipment. Red Herring reviewed Spectros in a recent market report in which the journal predicted the total market for optical products in optical molecular detection, imaging, and treatment guidance will grow to $12 billion annually over the next five years.

ABOUT SPECTROS: Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead T-Stat product became the first FDA-approved medical device for the detection of ischemia, an insufficient blood flow to tissue. Spectros is developing follow-on molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern.

ABOUT THERMO FISHER SCIENTIFIC, INC. (NYSE: TMO): Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics..

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. The "About Thermo Fisher Scientific" text is fair-use quoted from Yahoo Finance Business Summary, May 4, 2009. T-Stat is a registered trademark of the Spectros Corporation.)

For further information, contact Ms. Elizabeth van Thillo, Marketing, Spectros Corporation, at info@spectros.com or 650/529.2865


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
2. Fluorescent glass SRMs are new tool for spectroscopy
3. Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing
4. Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
5. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
6. Cardiogenesis Corporation to Report First Quarter 2009 Results on May 14th
7. Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009
8. Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program
9. ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
11. Volcano Corporation Schedules First Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... New York, NY (PRWEB) , ... January 24, ... ... index (BMI), larger waist circumference, and increased serum leptin levels had a positive ... study. The study published in the International Neurourology Journal involved ...
(Date:1/24/2017)... ... 24, 2017 , ... Nor-Tech’s leading-edge demo cluster is proving ... Intel KNL. , Currently Cal Tech researchers are testing their code on ... cluster is a no-cost, no-strings opportunity for current and prospective clients to test-drive ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward Buckler, Ph.D., a research ... National Academy of Sciences Prize in Food and Agriculture Sciences. He is being ... National Academy of Sciences (NAS) Prize in Food and Agriculture Sciences was established ...
(Date:1/24/2017)... According to a new market ... Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology ... Companies, CRO) - Global Forecast to 2021", published by ... Market for the forecast period of 2016 to 2021. ... by 2021 from USD 73.3 Million in 2016, growing ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):